Hypophagia and body weight loss by tirzepatide are accompanied by fewer GI adverse events compared to semaglutide in preclinical models

Journal:
Science Advances
Published:
DOI:
10.1126/sciadv.adu1589
Affiliations:
5
Authors:
17
Go to article
Institutions Authors Share
University of Pennsylvania Health System (UPHS), United States of America (USA)
11.666667
11.666667
 0.69
Lilly, United States of America (USA)
4.000000
 0.24
University of Southern California (USC), United States of America (USA)
1.333333
 0.08
Interested in Pharmacology and Pharmaceutical Sciences?